Compare PTRN & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTRN | LIVN |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | 2025 | 1993 |
| Metric | PTRN | LIVN |
|---|---|---|
| Price | $12.75 | $63.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $19.89 | ★ $62.43 |
| AVG Volume (30 Days) | ★ 825.9K | 597.3K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,293,676,000.00 | $1,348,962,000.00 |
| Revenue This Year | $39.02 | $12.25 |
| Revenue Next Year | $24.87 | $6.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 67.86 | 8.63 |
| 52 Week Low | $12.00 | $32.48 |
| 52 Week High | $20.10 | $65.57 |
| Indicator | PTRN | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 66.01 |
| Support Level | N/A | $61.81 |
| Resistance Level | N/A | $64.45 |
| Average True Range (ATR) | 0.00 | 1.96 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 0.00 | 84.88 |
Pattern Group Inc is an ecommerce accelerator, uses its technology platform, data science and a team of experts to drive growth for brands. The Company acquires inventory from brand partners to sell to consumers, enabling full control over content, pricing, logistics and customer service. Brand partners that contract with the Company operate in various industries including health and wellness, beauty and personal care, home and lifestyle, pet, sports and outdoors and consumer electronics.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.